Uncategorized
STAT+: Astellas treatment offers new hope to a devastated rare disease community
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.
Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.
Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption.